Zevra Therapeutics (ZVRA) Announces Board of Directors and Leadership Changes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Zevra Announces Board of Directors and Leadership Changes
May 8, 2023 7:30 AM EDTCELEBRATION, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced changes to the Companys Board of Directors (Board) and leadership. At the Companys recent 2023 Annual Meeting of Stockholders (Annual Meeting), Zevra shareholders elected John B. Bode, Douglas W. Calder and Corey Watton to Zevras Board. Additionally, as previously announced, Wendy L. Dixon, Ph.D., joined the Zevra Board on the date of the Annual Meeting. After the Annual Meeting, Zevras newly configured Board met and unanimously approved... More
